Switchable CAR-T Cell Engraftment Without Lymphodepleting Chemotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional CAR-T cell therapies require high cell doses and non-myeloablative lymphodepleting chemotherapy preconditioning, which is costly and increases patient vulnerability to infections, making them less effective and more complex.
Innovation Solution
The use of a switchable CAR-T (sCAR-T) platform that allows for engraftment and expansion of engineered T cells without prior lymphodepletion, utilizing a chimeric antigen receptor-T cell switch molecule and complementary CAR-T cells with a targeting moiety, enabling cyclical activation and reducing the need for chemotherapy and high cell doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T cell therapy is administered, then tumor cell recognition and elimination is achieved, but high cell doses and lymphodepleting chemotherapy preconditioning are required, increasing treatment complexity and patient vulnerability
Solution Approach 1:
The CAR-T cell is divided into two separate components: (1) a modified T cell expressing a CAR with a specific binding domain, and (2) a separate switch molecule containing the complementary binding domain. This segmentation allows the T cell to be administered without lymphodepletion, while the switch molecule is administered separately to activate the CAR-T cell only when needed, thereby reducing treatment complexity and patient vulnerability while maintaining tumor cell elimination capability
Solution Approach 2:
The switch molecule acts as an intermediary that bridges the CAR-T cell and the target antigen. Instead of directly activating the CAR-T cell through antigen binding, the switch molecule serves as a controllable mediator that can be administered independently to trigger CAR-T cell activation. This intermediary approach enables precise control over CAR-T cell activity and eliminates the need for lymphodepleting chemotherapy preconditioning
2Reliability
If conventional CAR-T cell therapy is administered, then therapeutic effect is achieved, but lymphodepleting chemotherapy preconditioning is required, increasing patient vulnerability to infections
Solution Approach 1:
The invention extracts and removes the lymphodepleting chemotherapy preconditioning step from the conventional CAR-T therapy protocol. By redesigning the CAR-T cell with a switchable activation mechanism, the therapy achieves its therapeutic effect without requiring the harmful lymphodepleting chemotherapy that causes patient vulnerability to infections
Solution Approach 2:
The T cell is pre-modified ex vivo to express the CAR with the specific binding domain, but remains inactive until the switch molecule is administered. This preliminary preparation allows the T cell to be ready for action without requiring lymphodepleting chemotherapy, thereby preventing patient vulnerability to infections while maintaining the ability to achieve therapeutic effect when activated
3Reliability
If conventional CAR-T cell therapy is administered, then immune system reprogramming is achieved, but high cell doses are required, increasing treatment cost and manufacturing complexity
Solution Approach 1:
The invention combines the CAR expression and the switchable activation mechanism into a single T cell platform. By merging these functions, the system achieves immune system reprogramming with lower cell doses, as the switch molecule can be administered to activate and amplify the effect of fewer CAR-T cells, thereby reducing treatment cost and manufacturing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective cancer treatment without lymphodepletion, reducing patient vulnerability, treatment complexity, and costs, while allowing for lower cell doses and improved manufacturing efficiency.
Implementation Method 1
a single-chain variable fragment (scFv) that specifically binds to the CAR-ID
Implementation Method 2
the targeting moiety in the switch molecule specifically binds to a cell surface target molecule in the subject
Data Source
AI summary
The invention novel methods for engrafting or expanding a switchable engineered effector cell (e.g., CAR-T cell) in a subject who has not undergone lymphodepleting (LD) chemotherapy. The methods entail administering to a subject a switchable effector platform (e.g., sCAR-T platform). The platform includes a switch molecule that specifically binds to a target molecule on the surface of a cell in the subject, and a complementary engineered effector cell (e.g., CAR-T cell) containing a CAR extracellular domain that specifically binds to a CAR-interacting domain in the switch molecule. Some methods of the invention are directed to treating or promoting regression of tumors in subjects who have not undergone lymphodepleting (LD) chemotherapy.